Diabetic Retinopathy Research & Clinical Trials

Sponsor - Kodiak Sciences (Open to Enrollment)

Study: GLOW KS301P106
A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
https://clinicaltrials.gov/ct2/show/NCT05066230?term=GLOW&draw=2&rank=6

Sponsor -  OcuTerra (Recruitment/Not yet Open)

Study: OTT166-201
A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)

Sponsor - F. Hoffman-La Roche Ltd. (Open to Enrollment)  

Study: CANBERRA BP41321 
A RANDOMIZED, DOUBLE-MASKED, 48-WEEK, PARALLEL-GROUP, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RG7774 IN PATIENTS WITH DIABETES MELLITUS TYPE 1 OR TYPE 2 WITH TREATMENT-NAÏVE DIABETIC RETINOPATHY
https://clinicaltrials.gov/ct2/show/NCT04265261?term=CANBERRA&draw=2&rank=1

Sponsor - F. Hoffmann-La Roche Ltd. (Closed to Enrollment) 

Study: PAVILION GR41675 
A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINPATHY (PAVILION)
https://clinicaltrials.gov/ct2/show/NCT04503551?term=PAVILION&draw=2&rank=1

Previous Diabetic Retinopathy (DR) Studies:

Sub-Investigator, 2016 - 2019
Sponsor: Regeneron
Study: PANORAMA
A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY
https://clinicaltrials.gov/ct2/show/NCT02718326?term=PANORAMA&rank=3

Principal Investigator, 2017 - 2019
Sponsor: Aerpio
Study: TIME-2b

PHASE 2 DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF SUBCUTANEOUSLY ADMINISTERED AKB-9778 15 MG ONCE DAILY OR 15 MG TWICE DAILY FOR 12 MONTHS IN PATIENTS WITH MODERATE TO SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY
https://clinicaltrials.gov/ct2/show/NCT03197870?term=TIME-2b&recrs=ab&rank=1

Sub-Investigator, 2007 - 2009
Protocol FVF4296s: An Open-Label Study to Determine the Dynamics of Regression of Neovascularization in Proliferative Diabetic Retinopathy Following Treatment with Intravitreal Ranibizumab.